Thalidomide: A Revolutionary Medication for Multiple Myeloma and Leprosy
Thalidomide is an immunomodulatory drug (IMiD) that has made significant contributions to the treatment of multiple myeloma and erythema nodosum leprosum (ENL), a complication of leprosy. Despite its history of causing birth defects, it is now safely used under strict guidelines, primarily in cancer and leprosy management.
Mechanism of Action
Thalidomide works by modulating the immune system. It inhibits TNF-alpha (tumor necrosis factor), a cytokine involved in inflammation. Thalidomide also affects the growth of blood vessels (angiogenesis) and induces apoptosis(programmed cell death) in cancer cells.
Indications
● Multiple Myeloma: Often used in combination with other chemotherapy agents to treat this cancer.
● Leprosy: Specifically for erythema nodosum leprosum (ENL), a painful inflammatory complication of leprosy.
Dosage and Administration
● Multiple Myeloma: Typically 200 mg once daily at bedtime, increasing as needed based on clinical response. It is generally used in combination with dexamethasone.
● Leprosy (ENL): 100-300 mg daily at bedtime, adjusted and tapered based on patient tolerance.
Side Effects
● Common: Drowsiness, constipation, peripheral neuropathy (nerve damage), and dizziness.
● Serious: Teratogenic effects (birth defects), deep vein thrombosis, and neuropathy.
Pregnancy Category: Category X – Not recommended during pregnancy due to severe birth defects.
Common Brands
● Thalomid, Thycad, Thaloda